<DOC>
	<DOCNO>NCT02354170</DOCNO>
	<brief_summary>The goal study assess efficacy safety mifepristone 300 900-mg once-daily dosing mouth 4 week patient central serous chorioretinopathy .</brief_summary>
	<brief_title>Short-Term Oral Mifepristone Central Serous Chorioretinopathy</brief_title>
	<detailed_description>- Prospective , randomize , double-masked , placebo-controlled dose-ranging study - Eligible patient CSC , symptom blur distorted vision , presence sub-retinal fluid document optical coherence tomography ( OCT ) central foveal sub-field - Only one eye participant include study , although eye evaluate . In patient bilateral CSC , eye sub-foveal fluid OCT study eye . - Patients evaluate treated one two study center : Ophthalmic Consultants Boston ( OCB ) , 50 Staniford St. , Suite 600 , Boston , MA Bay Area Retina Associates ( BARA ) , 122 La Casa Via , Suite 223 , Walnut Creek , CA - All participant receive standard ophthalmic examination well fluorescein indocyanine green angiography macular OCT per protocol . - 30 patient enrol , follow : 10 patient randomly assign Cohort 1 , take one ( 1 ) mifepristone 300-mg tablet ( 300 mg total dose ) daily mouth 4 week . 10 patient randomly assign Cohort 2 , take three ( 3 ) mifepristone 300-mg tablet ( 900 mg total dose ) daily mouth 4 week . 10 patient randomly assign Cohort 3 , take placebo tablet ( ) daily mouth 4 week . - After complete enrollment criterion , subject randomize 1:1:1 Cohort 1 , 2 , 3 . - During Baseline visit Week 2 , 4 , 8 visit , subject laboratory test follow lab test : serum electrolyte , BUN creatinine , liver function test - Prior initiate dose study drug , woman child-bearing potential ( WOCBP ) serum beta-HCG assessed rule pregnancy ; WOCBP enrol study require use barrier contraception throughout study . - Adverse event track visit ( see `` Data Safety Monitoring Plan '' )</detailed_description>
	<mesh_term>Central Serous Chorioretinopathy</mesh_term>
	<mesh_term>Mifepristone</mesh_term>
	<criteria>1 . Diagnosis central serous chorioretinopathy ( CSC ) symptoms 6 week prior document episode subretinal fluid ; patient previous treatment CSC may include 2 . Presence subretinal fluid document optical coherence tomography ( OCT ) central foveal subfield 3 . Age 18 4 . Willing able comply clinic visit studyrelated procedure 5 . Ability give write informed consent 1 . Age less 18 2 . Persons impair decisionmaking ability . 3 . Women know breastfeeding , pregnant actively try conceive . 4 . Additional eye disease affect macula , posterior retina , ocular medium would limit prevent acquisition OCT angiographic image . 5 . At screening , serum potassium &lt; LLN , BUN &gt; 1.5 ULN , serum creatinine &gt; 1.5 ULN , AST &gt; 1.5 ULN , ALT &gt; 1.5 ULN , bilirubin &gt; 1.5 ULN , alkaline phosphatase &gt; 1.5 ULN , serum albumin &gt; 1.5 ULN &lt; LLN . 6 . Intraocular surgery ( include cataract surgery ) study eye within 60 day precede baseline . 7 . Active intraocular inflammation ( grade trace ) study eye . 8 . Patients take simvastatin , lovastatin , CYP3A substrates narrow therapeutic range , cyclosporine , dihydroergotamine , ergotamine , fentanyl , pimozide , quinidine , sirolimus , tacrolimus . 9 . Patients require concomitant treatment systemic corticosteroid serious medical condition illness ( e.g. , immunosuppression organ transplantation ) . 10 . Women history unexplained vaginal bleeding woman endometrial hyperplasia atypia endometrial carcinoma . 11 . Patients prior hypersensitivity reaction mifepristone product component . 12 . Patients know hypersensitivity fluorescein indocyanine green dye . WOCBP must willing practice adequate contraception study ( adequate contraceptive measure include intrauterine device [ IUD ] ; bilateral tubal ligation ; condom plus contraceptive sponge , foam , jelly , diaphragm plus contraceptive sponge , foam , jelly ) . Postmenopausal woman must amenorrheic least 12 month order consider child bear potential . Pregnancy test contraception require woman document hysterectomy tubal ligation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Central Serous Chorioretinopathy , CSC</keyword>
</DOC>